TY - JOUR
T1 - Clinical Response to Combined Therapy of Cyclosporine and Prednisone
AU - Gensure, Robert C.
N1 - Funding Information:
Funding for the Summit and publication of this article was provided by the National Alopecia Areata Foundation. Informed consent for publication provided by the patient's father.
Publisher Copyright:
© 2013 The Society for Investigative Dermatology, Inc
PY - 2013/12
Y1 - 2013/12
N2 - Reported is a patient with severe alopecia areata, multiple autoimmune diseases (chronic lymphocytic thyroidis, primary ovarian failure), and Down syndrome. She had a poor response to topical treatment with glucocorticoids and minoxidil, but showed some improvement with glucocorticoid injections. At the time of evaluation, she had hair loss on 85–90% of her scalp. She was treated initially with oral prednisone 50 mg per day for 2 weeks, followed by a 3-month course of prednisone 10 mg per day and cyclosporine 125 mg (4 mg kg−1) two times per day. She responded well with excellent regrowth of hair on the scalp, and prednisone was tapered and ultimately discontinued. Importantly, her parents noted marked improvement in sense of well-being. Several months after discontinuing treatment, she developed hyperpigmentation on the trunk consistent with confluent and reticulated papillomatosis; she has several known risk factors for this disorder, but it is not clear if this is related to her previous treatment.
AB - Reported is a patient with severe alopecia areata, multiple autoimmune diseases (chronic lymphocytic thyroidis, primary ovarian failure), and Down syndrome. She had a poor response to topical treatment with glucocorticoids and minoxidil, but showed some improvement with glucocorticoid injections. At the time of evaluation, she had hair loss on 85–90% of her scalp. She was treated initially with oral prednisone 50 mg per day for 2 weeks, followed by a 3-month course of prednisone 10 mg per day and cyclosporine 125 mg (4 mg kg−1) two times per day. She responded well with excellent regrowth of hair on the scalp, and prednisone was tapered and ultimately discontinued. Importantly, her parents noted marked improvement in sense of well-being. Several months after discontinuing treatment, she developed hyperpigmentation on the trunk consistent with confluent and reticulated papillomatosis; she has several known risk factors for this disorder, but it is not clear if this is related to her previous treatment.
UR - http://www.scopus.com/inward/record.url?scp=84907227601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84907227601&partnerID=8YFLogxK
U2 - 10.1038/jidsymp.2013.23
DO - 10.1038/jidsymp.2013.23
M3 - Article
C2 - 24326561
AN - SCOPUS:84907227601
SN - 1087-0024
VL - 16
SP - S58
JO - Journal of Investigative Dermatology Symposium Proceedings
JF - Journal of Investigative Dermatology Symposium Proceedings
IS - 1
ER -